Status:
UNKNOWN
Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Cervical Cancer
Eligibility:
FEMALE
18-75 years
Phase:
PHASE1
Brief Summary
Chemotherapy is the current standard treatment for unresectable recurrent cervical carcinoma after radiotherapy or distant metastasis of cervical carcinoma. The most effective regimens are cisplatin-b...
Detailed Description
Chemotherapy is the current standard treatment for unresectable recurrent cervical carcinoma after radiotherapy or distant metastasis of cervical carcinoma. The most effective regimens are cisplatin-b...
Eligibility Criteria
Inclusion
- recurrent cervical cancer
- HPV 16 infection
- Previously received cisplatin ot 5-FU based chemotherapy or refused to receive chemotherapy
- HLA-A2 haplotype
- Older than 20 years old
- ECOG I or II
- Life expectancy longer than 3 months
- Adequate bone marrow reserve
- pregnancy test: negative
- Informed consent obtained
Exclusion
- CNS metastasis
- Acute or chronic infection
- Pregnant or lactating women
- Asthma
- Cardiac diseases such as heart failure, unstable angina, arrhythmia, myocardial infarction
- Autoimmune disease
- Previously other cancers (except basal cell cancer)
- Without chemotherapy, biotherapy for more than 6 weeks
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00155766
Start Date
January 1 2003
End Date
March 1 2006
Last Update
December 20 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan